Royal Bank of Canada increased its position in Radius Health, Inc. (NASDAQ:RDUS) by 25.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 405,825 shares of the biopharmaceutical company’s stock after buying an additional 81,414 shares during the period. Royal Bank of Canada owned about 0.93% of Radius Health worth $18,356,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. State of Wisconsin Investment Board bought a new position in shares of Radius Health during the 2nd quarter valued at about $1,176,000. OppenheimerFunds Inc. boosted its holdings in shares of Radius Health by 0.3% during the 1st quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after purchasing an additional 831 shares during the last quarter. American International Group Inc. boosted its holdings in shares of Radius Health by 7.1% during the 1st quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 1,284 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Radius Health by 98,245.6% during the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after purchasing an additional 2,628,070 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in shares of Radius Health during the 2nd quarter valued at about $25,589,000.
In other news, CFO Jose Carmona bought 3,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were bought at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the acquisition, the chief financial officer now directly owns 3,000 shares of the company’s stock, valued at approximately $98,490. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was purchased at an average price of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the acquisition, the insider now directly owns 5,298,799 shares in the company, valued at $194,730,863.25. The disclosure for this purchase can be found here. Insiders acquired a total of 469,100 shares of company stock worth $16,328,382 over the last quarter. 15.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. (RDUS) Position Lifted by Royal Bank of Canada” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.themarketsdaily.com/2017/10/12/radius-health-inc-rdus-position-lifted-by-royal-bank-of-canada.html.
Shares of Radius Health, Inc. (NASDAQ:RDUS) opened at 36.77 on Thursday. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $55.97. The stock’s market capitalization is $1.60 billion. The company has a 50-day moving average of $36.68 and a 200-day moving average of $38.72.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same quarter last year, the firm earned ($1.01) EPS. Equities research analysts anticipate that Radius Health, Inc. will post ($5.55) EPS for the current year.
Several research analysts have commented on RDUS shares. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. Finally, Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $52.17.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.